Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.

Fiche publication

Date publication

mars 2022

Journal

World journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE CARVALHO BITTENCOURT Marcelo

Tous les auteurs :
Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35317057

Résumé

Crohn's disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been demonstrated; however, little information is available on serum adalimumab (ADA) concentrations and remission of perianal fistulas in such patients.